Kidney International Reports最新文献

{"title":"Osteoporosis and CKD-Metabolic Bone Disease Under the Same Umbrella: Insights From a Joint Scientific Symposium","authors":"David W. Dempster ,&nbsp;Pieter Evenepoel ,&nbsp;Thomas L. Nickolas ,&nbsp;Ziad A. Massy ,&nbsp;Sandro Mazzaferro ,&nbsp;Nicholas C. Harvey ,&nbsp;Paul D. Miller ,&nbsp;Michael Pazianas","doi":"10.1016/j.ekir.2026.106362","DOIUrl":"10.1016/j.ekir.2026.106362","url":null,"abstract":"<div><div>Osteoporosis and chronic kidney disease (CKD)–metabolic bone disease (MBD) (CKD-MBD) are increasingly recognized as overlapping conditions, particularly in the aging population. Declining renal function and skeletal fragility often coexist, because CKD-MBD may develop in a skeleton already compromised by preexisting osteoporosis. Adynamic bone, often resulting from excessive suppression of parathyroid hormone (PTH) and now a common form of renal osteodystrophy (ROD), may histologically resemble low-turnover osteoporosis; distinguishing between the 2 under light microscopy remains difficult, and reliable differentiation often depends on clinical context. Nevertheless, nephrologists and nonnephrologist bone specialists frequently work in parallel rather than in collaboration.This separation has contributed to persistent diagnostic gaps and fragmented management, especially in patients with advanced CKD. Advances in imaging, biochemical markers, and bone histomorphometry have improved insight into disease mechanisms; however, limitations in current diagnostic approaches remain. Osteoporosis therapies are frequently underused in CKD, despite growing evidence supporting efficacy and safety across a broader range of kidney function than previously assumed. Despite efforts to refine the definition of osteoporosis beyond bone mineral density (BMD) alone, clinical misclassification continues.Beyond skeletal health, vascular calcification (VC)—driven by disordered calcium–phosphate homeostasis—remains insufficiently prioritized in clinical decision-making, despite its strong association with cardiovascular morbidity and mortality in CKD. Emerging concepts, such as intermittent PTH administration, an established treatment in osteoporosis, illustrate the potential for interventions that may restore mineral balance and improve skeletal integrity in selected CKD populations. Whether such strategies can also favorably influence cardiovascular risk remains uncertain and warrant investigation. This integrated framework may improve interdisciplinary care.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"11 5","pages":"Article 106362"},"PeriodicalIF":5.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147388369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"WCN26-3792 Mechanistic Kidney Effects of Semaglutide by Baseline SGLT2i Use in Type 2 Diabetes: A Post-hoc Analysis of the REMODEL Trial","authors":"David Cherney ∗ ,&nbsp;Radica Alicic ,&nbsp;Milenta Chacko ,&nbsp;Lynette Driscoll ,&nbsp;Emma Olesen ,&nbsp;Prachi Priyadarshini ,&nbsp;Vikas Sridhar ,&nbsp;Katherine Tuttle ,&nbsp;Petter Bjornstad","doi":"10.1016/j.ekir.2026.106504","DOIUrl":"10.1016/j.ekir.2026.106504","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"11 5","pages":"Article 106504"},"PeriodicalIF":5.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147849971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Moving Mendelian Randomization From Traditional Risk Factors to Molecular Targets for Drug Development and Clinical Trials in Nephrology","authors":"Abigail J. Berube ,&nbsp;Eryn Yu ,&nbsp;Pukhraj S. Gaheer ,&nbsp;Matthew B. Lanktree","doi":"10.1016/j.ekir.2026.106350","DOIUrl":"10.1016/j.ekir.2026.106350","url":null,"abstract":"<div><div>Mendelian randomization leverages the random assortment of alleles at conception to investigate how genetically mediated changes in an exposure affect an outcome while minimizing concerns related to reverse causation and unmeasured confounding. Initially applied to assess the causal impact of modifiable traditional risk factors as mediators of disease risk, Mendelian randomization studies now incorporate large-scale multiomic datasets providing valuable insights for drug target discovery. By analyzing <em>cis</em> genetic changes that affect gene activity or protein levels—using advancing techniques like single-cell sequencing and proteomics—Mendelian randomization can identify new therapeutic targets, predict drug target efficacy and effect size before trial development, anticipate adverse effects, reduce late-stage trial failures, and identify opportunities for drug repurposing. This review explains the basic principles, broad applications, and inherent limitations of Mendelian randomization in drug-target identification, validation, and repurposing within the context of kidney disease. Many retrospective examples of concordant conclusions from clinical trials and Mendelian randomization studies have been reported including statins, allopurinol, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists. Genetic evidence should now be prospectively evaluated for all drugs attempting to traverse the “translational valley of death” in drug development. We summarize current examples, spotlight emerging analytic methodologies such as phenome-wide Mendelian randomization and integrated multiomics, and discuss future directions to accelerate drug development in nephrology.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"11 5","pages":"Article 106350"},"PeriodicalIF":5.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147388363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"WCN26-6966 EFFECT OF A 12-WEEK INTRADIALYTIC CYCLING INTERVENTION ON HEMODIALYSIS-INDUCED MYOCARDIAL STUNNING: A MULTI-CENTRE RANDOMIZED CONTROLLED TRIAL (TICKERS_HD)","authors":"Paul N. Bennett ,&nbsp;Jarrin D. Penny ,&nbsp;Christopher W. McIntyre ,&nbsp;Jessica Vanderlinden ,&nbsp;Megan Borkum ,&nbsp;Shilpanjali Jesudason ,&nbsp;Mercedeh Kiaii ,&nbsp;Justin Presseau ,&nbsp;Claudio Rigatto ,&nbsp;Mitra Shirazi ,&nbsp;Anita Soni ,&nbsp;Brett Tarca ,&nbsp;Stephanie Thompson ,&nbsp;Jennifer M. MacRae ,&nbsp;Clara Bohm ∗","doi":"10.1016/j.ekir.2026.106509","DOIUrl":"10.1016/j.ekir.2026.106509","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"11 5","pages":"Article 106509"},"PeriodicalIF":5.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147849815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Defining Relationships Among Tests for Kidney Transplant Antibody-Mediated Rejection” [Kidney International Reports Volume 10, Issue 9, September 2025, Pages 3225-3238]","authors":"Katelynn S. Madill-Thomsen ,&nbsp;Luis G. Hidalgo ,&nbsp;Zachary P. Demko ,&nbsp;Philippe M. Gauthier ,&nbsp;Adam Prewett ,&nbsp;Dave Lowe ,&nbsp;Jessica J. Chang ,&nbsp;Martina Mackova ,&nbsp;Klemens Budde ,&nbsp;Jonathan S. Bromberg ,&nbsp;Philip F. Halloran ,&nbsp;Trifecta-Kidney Study Group","doi":"10.1016/j.ekir.2026.106407","DOIUrl":"10.1016/j.ekir.2026.106407","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"11 5","pages":"Article 106407"},"PeriodicalIF":5.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147388315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"WCN26-7699 B-CELL–TARGETED THERAPY FOR IDIOPATHIC NEPHROTIC SYNDROME: RESULTS OF THE PHASE III, GLOBAL, MULTICENTER INSHORE TRIAL ASSESSING OBINUTUZUMAB VS MYCOPHENOLATE MOFETIL","authors":"Julien Hogan ∗ ,&nbsp;Larry A. Greenbaum ,&nbsp;Kandai Nozu ,&nbsp;Malgorzata Mizerska-Wasiak ,&nbsp;Andreia Watanabe ,&nbsp;Andrea Angeletti ,&nbsp;Kenneth Lieberman ,&nbsp;Jie Ding ,&nbsp;Toru Uchimura ,&nbsp;Franz Schaefer ,&nbsp;Theodore A. Omachi ,&nbsp;Ben Lanza ,&nbsp;Benoît Meger ,&nbsp;Heather Boston ,&nbsp;Patricia B. Lehane","doi":"10.1016/j.ekir.2026.106510","DOIUrl":"10.1016/j.ekir.2026.106510","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"11 5","pages":"Article 106510"},"PeriodicalIF":5.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147849969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"WCN26-5829 EFFICACY AND SAFETY OF FINERENONE AND EMPAGLIFLOZIN IN PATIENTS WITH INITIAL DECLINE IN ESTIMATED GLOMERULAR FILTRATION RATE: A CONFIDENCE TRIAL PRESPECIFIED ANALYSIS","authors":"Hiddo J.L. Heerspink ∗ ,&nbsp;Amy K. Mottl ,&nbsp;Julio Rosenstock ,&nbsp;Masaomi Nangaku ,&nbsp;Janet B. McGill ,&nbsp;Jennifer B. Green ,&nbsp;Peter Rossing ,&nbsp;Muthiah Vaduganathan ,&nbsp;Johannes F.E. Mann ,&nbsp;Jose Luis Gorriz ,&nbsp;Na Li ,&nbsp;Meike Brinker ,&nbsp;Charlie Scott ,&nbsp;Mario Berger ,&nbsp;Rajiv Agarwal","doi":"10.1016/j.ekir.2026.106507","DOIUrl":"10.1016/j.ekir.2026.106507","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"11 5","pages":"Article 106507"},"PeriodicalIF":5.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147849814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"WCN26-4303 Effect of finerenone and an SGLT2 inhibitor on the urine proteome: A CONFIDENCE analysis","authors":"Mario Berger ∗ ,&nbsp;Mark Andre De la Rambelje ,&nbsp;Adam Skubala ,&nbsp;Sebastian Voss ,&nbsp;Aiden MacNamara ,&nbsp;Agnese Petrera ,&nbsp;Johanna Mielke ,&nbsp;Karoline Holler ,&nbsp;Rania Dayoub ,&nbsp;Byung Wan Lee ,&nbsp;Jonathan Barratt ,&nbsp;Rajiv Agarwal ,&nbsp;David Cherney ,&nbsp;Hiddo J.L. Heerspink ,&nbsp;Peter Rossing","doi":"10.1016/j.ekir.2026.106505","DOIUrl":"10.1016/j.ekir.2026.106505","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"11 5","pages":"Article 106505"},"PeriodicalIF":5.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147850013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"WCN26-5982 RANDOMIZED EMBEDDED ADAPTIVE PLATFORM CLINICAL TRIAL IN SOUTH ASIAN KIDNEY BIOPSY-PROVEN PRIMARY GLOMERULAR DISEASES: MULTI-CENTER, MULTI-ARM AND MULTI-STAGE- THE STORY SO FAR","authors":"SUCEENA ALEXANDER ,&nbsp;SELVIN SUNDAR RAJ ∗ ,&nbsp;BABAK CHOODARI-OSKOOEI ,&nbsp;PRASANNA SAMUEL ,&nbsp;JONATHAN BARRATT ,&nbsp;IA-GRACE-IGANT INVESTIGATORS","doi":"10.1016/j.ekir.2026.106508","DOIUrl":"10.1016/j.ekir.2026.106508","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"11 5","pages":"Article 106508"},"PeriodicalIF":5.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147850014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevention of Recurrent Kidney Stones: A CARI Guidelines Summary","authors":"David J. Tunnicliffe ,&nbsp;Lyn Lloyd ,&nbsp;Adam Mullan ,&nbsp;Andrew J. Mallett ,&nbsp;Ieuan Wickham ,&nbsp;Nadya York ,&nbsp;Mia E. Abdy ,&nbsp;Brydee Cashmore ,&nbsp;Hicham Cheikh Hassan ,&nbsp;Matthew Jose","doi":"10.1016/j.ekir.2026.106346","DOIUrl":"10.1016/j.ekir.2026.106346","url":null,"abstract":"<div><h3>Introduction</h3><div>The incidence of kidney stones is increasing in Australia and Aotearoa New Zealand, increasing pressure on emergency departments for acute pain management and stretching nephrology and dietetics services tasked with preventing recurrence. To address this, the Caring for Australians and New ZealandeRs with kidney Impairment (CARI) guidelines provide evidence-based recommendations that complement urological and surgical care, contextualized for our region and developed with input from people with lived experience.</div></div><div><h3>Methods</h3><div>Guidelines were developed through a 5-stage process aligned with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. A multidisciplinary working group formulated Population Intervention/Exposure Comparator Outcome Methodology questions, and a group of consumers in a dedicated workshop scoped guideline topics. A systematic literature review was conducted, prioritizing high-quality evidence that was critically appraised and synthesized. Recommendations were drafted using the GRADE Evidence-to-Decision framework, incorporating perspectives of lived experience throughout.</div></div><div><h3>Results</h3><div>These guidelines provide recommendations on the diagnosis, metabolic evaluation, and management to prevent recurrent kidney stones. Nutrition therapy provided by dietitians with expertise is a fundamental and cost-effective intervention for preventing recurrent kidney stones. Although nutrition therapy should precede pharmacological interventions in most cases, the use of potassium citrate and thiazide diuretics may be considered when nutrition therapy alone is insufficient.</div></div><div><h3>Conclusion</h3><div>These CARI guidelines address a critical gap in the management of kidney stones in Australia and New Zealand by providing evidence-based, contextualized recommendations to support nephrologists, dietitians with expertise in kidney stones, and other health professionals in delivering consistent, high-quality care that reduces kidney stone recurrence and improves outcomes.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"11 5","pages":"Article 106346"},"PeriodicalIF":5.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147388314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}